Tandem Diabetes Care, Inc.
TNDM
Updated: 23/09/2026, 22:08:48
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
No summaries found.
- Share price
- $16.38
- Market cap
- $1.12B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- John F. Sheridan
- Employees
- 2,500
- IPO date
- 14/11/2013
- Beta
- 1.556
- Last dividend
- $0.00
- Day range
- $15.87 – $17.56
- 52-week range
- $11.46 – $29.65
- 1-day performance
- -6.40%
- 1-year performance
- 42.93%
- Current drawdown (1Y)
- -44.76%
- CIK
- 0001438133
- CUSIP
- 875372203
- ISIN
- US8753722037
- Created
- 07/12/2025, 14:36:22
- Last update
- 23/09/2026, 22:08:48
Track Tandem Diabetes Care, Inc. with an AI analyst
See which prediction-market events move TNDM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 20:28:31
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?
Zacks Investment Research • STOCK • 05/06/2026, 12:57:15
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
Zacks Investment Research • STOCK • 04/06/2026, 15:01:57
TNDM Stock: What to Know About Tandem's 2026 Reset
Zacks Investment Research • STOCK • 02/06/2026, 14:01:31
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Zacks Investment Research • STOCK • 14/05/2026, 11:40:27
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 05:10:46
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research • STOCK • 12/05/2026, 12:35:33
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 10/05/2026, 08:41:14
Tandem Diabetes Care Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 03:07:24
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 07/05/2026, 21:30:23
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
GlobeNewsWire • STOCK • 27/03/2026, 10:00:00
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
Zacks Investment Research • STOCK • 18/03/2026, 08:20:40